TNF and rheumatoid arthritis: The UK-based ACT-MOVE study was part of the TOZURA programme and was designed to assess the real-world efficacy of TCZ-SC, as monotherapy or in combination with csDMARD therapy, for up to 1 year in RA patients with an inadequate response to csDMARDs and/or first TNF inhibitor.